low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is committed multi-year investment independent of economic cycles. However, financing conditions and investor risk appetite for speculative growth assets are highly cyclical, affecting ability to raise capital and stock valuation multiples. Patient enrollment in trials continues regardless of economic conditions.

High sensitivity through valuation channel. As a pre-revenue asset with cash flows 5-10+ years out, Janux is valued on discounted future earnings. Rising rates increase discount rates applied to distant cash flows, compressing valuations significantly (evidenced by -64.4% 1-year return during 2024-2025 rate environment). Higher rates also increase opportunity cost of holding cash-burning growth stocks versus bonds. Financing costs are minimal given negligible debt (0.02 D/E), but equity financing becomes more expensive as cost of capital rises.

growth - Pure speculative growth play attracting biotech specialists, venture-style investors, and momentum traders seeking multi-bagger returns from clinical success. Not suitable for value or income investors given no earnings, no dividends, and binary risk profile. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail investors with high risk tolerance. 64.4% drawdown indicates this attracts risk-seeking capital willing to endure extreme volatility for asymmetric upside potential.